LSD1 Antibody (B-9): sc-271720
- LSD1 Antibody (B-9) is a mouse monoclonal IgG1 κ LSD1 antibody, cited in 22 publications, provided at 200 µg/ml
- raised against amino acids 581-800 mapping near the C-terminus of LSD1 of human origin
- LSD1 Antibody (B-9) is recommended for detection of LSD1 of mouse, rat and human origin by WB, IP, IF and ELISA
- Anti-LSD1 Antibody (B-9) is available conjugated to agarose for IP; HRP for WB, IHC(P) and ELISA; and to either phycoerythrin or FITC for IF, IHC(P) and FCM
- also available conjugated to Alexa Fluor® 488, Alexa Fluor® 546, Alexa Fluor® 594 or Alexa Fluor® 647 for WB (RGB), IF, IHC(P) and FCM, and for use with RGB fluorescent imaging systems, such as iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- also available conjugated to Alexa Fluor® 680 or Alexa Fluor® 790 for WB (NIR), IF and FCM; for use with Near-Infrared (NIR) detection systems, such as LI-COR®Odyssey®, iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- TransCruz reagent for Gel Supershift and ChIP applications (sc-271720 X, 200 µg/0.1 ml)
- m-IgG Fc BP-HRP, m-IgG1 BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for LSD1 Antibody (B-9) for WB applications. These reagents are now offered in bundles with LSD1 Antibody (B-9) (see ordering information below).
QUICK LINKS
SEE ALSO...
LSD1 Antibody (B-9) is a mouse monoclonal IgG1 kappa light chain antibody that detects LSD1 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). LSD1 Antibody (B-9) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. LSD1, also known as lysine-specific histone demethylase 1, plays a crucial role in regulating histone methylation, which maintains chromatin structure and transcriptional activity, influencing cellular epigenetic states. LSD1 functions as a flavin-dependent amine oxidase that specifically removes one or two methyl groups from methyl-lysine-4 side chain of histone H3, a process vital for gene expression regulation. LSD1′s structure includes a SWIRM domain, a FAD-binding motif, and an amine oxidase domain, critical for enzymatic function and protein interactions. LSD1 associates with CoREST, a corepressor enhancing demethylation activity and protecting against proteasomal degradation, while PHF21A can inhibit LSD1′s activity. LSD1 co-localizes with androgen receptor in prostate cells, highlighting a role in androgen-receptor-dependent transcription, particularly significant in prostate cancer research.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
LSD1 Antibody (B-9) References:
- Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. | Shi, Y., et al. 2004. Cell. 119: 941-53. PMID: 15620353
- Methylation: lost in hydroxylation? | Trewick, SC., et al. 2005. EMBO Rep. 6: 315-20. PMID: 15809658
- Histone demethylation catalysed by LSD1 is a flavin-dependent oxidative process. | Forneris, F., et al. 2005. FEBS Lett. 579: 2203-7. PMID: 15811342
- An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. | Lee, MG., et al. 2005. Nature. 437: 432-5. PMID: 16079794
- LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. | Metzger, E., et al. 2005. Nature. 437: 436-9. PMID: 16079795
- Regulation of LSD1 histone demethylase activity by its associated factors. | Shi, YJ., et al. 2005. Mol Cell. 19: 857-64. PMID: 16140033
- Taking LSD 1 to a new high. | Wysocka, J., et al. 2005. Cell. 122: 654-8. PMID: 16143099
- LSD1 Histone Demethylase Assays and Inhibition. | Hayward, D. and Cole, PA. 2016. Methods Enzymol. 573: 261-78. PMID: 27372757
- Trends of LSD1 inhibitors in viral infections. | Zwergel, C., et al. 2018. Future Med Chem. 10: 1133-1136. PMID: 29787289
- Drug Design Concepts for LSD1-Selective Inhibitors. | Ota, Y. and Suzuki, T. 2018. Chem Rec. 18: 1782-1791. PMID: 30277644
- Targeting LSD1 for acute myeloid leukemia (AML) treatment. | Zhang, S., et al. 2021. Pharmacol Res. 164: 105335. PMID: 33285227
- Therapeutic potential of targeting LSD1/ KDM1A in cancers. | Zhang, X., et al. 2022. Pharmacol Res. 175: 105958. PMID: 34718134
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LSD1 Antibody (B-9) | sc-271720 | 200 µg/ml | $322.00 | |||
LSD1 Antibody (B-9): m-IgG Fc BP-HRP Bundle | sc-529250 | 200 µg Ab; 10 µg BP | $361.00 | |||
LSD1 Antibody (B-9): m-IgGκ BP-HRP Bundle | sc-522038 | 200 µg Ab, 40 µg BP | $361.00 | |||
LSD1 Antibody (B-9): m-IgG1 BP-HRP Bundle | sc-543415 | 200 µg Ab; 20 µg BP | $361.00 | |||
LSD1 Antibody (B-9) X | sc-271720 X | 200 µg/0.1 ml | $322.00 | |||
LSD1 Antibody (B-9) AC | sc-271720 AC | 500 µg/ml, 25% agarose | $424.00 | |||
LSD1 Antibody (B-9) HRP | sc-271720 HRP | 200 µg/ml | $322.00 | |||
LSD1 Antibody (B-9) FITC | sc-271720 FITC | 200 µg/ml | $336.00 | |||
LSD1 Antibody (B-9) PE | sc-271720 PE | 200 µg/ml | $349.00 | |||
LSD1 Antibody (B-9) Alexa Fluor® 488 | sc-271720 AF488 | 200 µg/ml | $364.00 | |||
LSD1 Antibody (B-9) Alexa Fluor® 546 | sc-271720 AF546 | 200 µg/ml | $364.00 | |||
LSD1 Antibody (B-9) Alexa Fluor® 594 | sc-271720 AF594 | 200 µg/ml | $364.00 | |||
LSD1 Antibody (B-9) Alexa Fluor® 647 | sc-271720 AF647 | 200 µg/ml | $364.00 | |||
LSD1 Antibody (B-9) Alexa Fluor® 680 | sc-271720 AF680 | 200 µg/ml | $364.00 | |||
LSD1 Antibody (B-9) Alexa Fluor® 790 | sc-271720 AF790 | 200 µg/ml | $364.00 |